We have determined the turnover rates for proapolipoprotein A-I (proapoA-I) and mature apolipoprotein A-I (apoA-I) in vivo in human and in rat. For the human study, high density lipoprotein (HDL)-associated -'HI-labeled proapoA-I (A-I isoform 1) and 131I-labeled mature apoA-I (A-I isoforms 3, 4, and 5) were injected simultaneously into two normal volunteers. Blood samples were obtained serially and HDL proapoA-I and mature apoA-I were separated by isoelectrofocusing for the determination of the associated radioactivity. Residence times of proapoA-I and mature apoA-I were 0.13 and 3.9 days and production rates were 9.0 and 9.3 mg/kg per day, respectively. Analysis of the specific activity curves suggested a complete proapoA-I to mature apoA-I precursor-product relationship. Proprotein conversion was virtually completed in 24 hr. For the rat study, HDL-and lymph chylomicron-(flotation constant Sf > 400 S) associated 125I-labeled proapoA-I and 131I-mature apoA-I were injected into fasted rats. Residence times of proapoA-I and mature apoA-I injected in association with HDL were 0.13 and 0.28 day, respectively, and for injection associated with chylomicrons the residence times were 0.08 and 0.26 day. When associated with chylomicrons, proapoA-I was converted more efficiently to the mature form. As in the human study, the results demonstrated a complete proapoA-I to mature apoA-I precursor-product relationship. Our data are consistent with the concepts that (i) conversion to mature apoA-I is the major proapoA-I catabolic fate in plasma; (it) mature apoA-I is conceivably derived solely from proapoA-I in plasma and proapoA-I is the major apoA-I form secreted in vivo; and (ii) a putative proapoA-I-chylomicron complex is the preferred substrate for the apoA-I propeptidase.
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Apolipoprotein A-I (apoA-I) is the major protein constituent of high density lipoproteins (HDL) and lymph chylomicrons. The liver and the intestine are the major, if not the only, sites of synthesis of apoA-I in human and rats (1) . In human, proapoA-I is synthesized as a precursor protein, preproapoA-I, of 267 amino acids (2, 3) . The prepeptide is 18 amino acids long and is cleaved intracellularly during vectoral translocation into the lumen of the rough endoplasmic reticulum, yielding a proprotein denoted proapoA-I (4, 5) . In vitro cell and tissue culture studies have shown that proapoA-I is the only form of apoA-I secreted (6) (7) (8) . In contrast, apoA-I circulates in plasma as a mixture of isoproteins numbered, from 1 to 5, which differ by a unit of charge (6, 9) . apoA-11 (proapoA-I) constitutes in plasma only a small fraction (<4%) of the total mass of circulating apoA-I, whereas apoA-I3, apoA-14, and apoA-I5 are the major plasma apoA-I isoproteins and are the "mature" forms of this apolipoprotein (6, 9) . The difference between the apoA-I isoprotein secretory pattern and that observed in plasma suggested that the newly secreted proform undergoes post-translational proteolytic cleavage while in plasma to the stable mature form(s) (6) . We recently have provided evidence that this conversion is actually occurring in vivo in the rat (10) . Human proapoA-I also is converted to the mature form while in the circulation, although this process has not been characterized quantitatively (11) . Furthermore, the possibility that proapoA-I might be directly catabolized has not been investigated. Studies conducted in vitro utilizing human or rat proapoA-I indicate that conversion may be relatively slow and, under the experimental conditions utilized, is only partially converted (430%) even after a prolonged incubation (12, 13) . In this report we provide in vivo evidence that human and rat proapoA-I are rapidly and efficiently converted to the mature product in a virtually quantitative fashion. Moreover, our data obtained in the rat suggest that the conversion is dependent upon the plasma concentration of certain lipoprotein fractions, in particular lymph chylomicrons.
MATERIALS AND METHODS
Isoprotein Isolation and Quantitation. Human proapoA-I (apoA-I isoprotein 1) and mature apoA-I (apoA-I isoproteins 3, 4, and 5) were isolated from thoracic duct lymph chylomicrons* as described in previous reports (9, 10) . Briefly, chylomicron apoA-I was initially purified by molecular sieve chromatography utilizing a Bio-Gel A-5 M column (1.5 x 190 cm; Bio-Rad) equilibrated with 0.1% NaDodSO4/0.1 M Tris-HCl, pH 7.4. proapoA-I and mature apoA-I were then isolated by preparative isoelectrofocusing (9) . Protein purity was checked by analytical isoelectrofocusing, NaDodSO4/ polyacrylamide gel electrophoresis, and two-dimensional gel electrophoresis with the first dimension being isoelectrofocusing from pH 4 to 6 (9) . The relative contents of proapoA-I and mature apoA-I in HDL were determined by a pyridine/water dye extraction method from two-dimensional gel electrophoretograms (14) stained with Coomassie blue R250. Because of the minute amounts of proapoA-I in normal human HDL, dye was eluted from a pool of eight two-dimensional gels and mean values obtained from three pools corresponding to a total of 24 normal subjects for apoA-I analysis of human HDL.
The isolation procedure for rat proapoA-I and mature apoA-I from mesenteric lymph chylomicrons has been described previously (10) . proapoA-I and mature apoA-I ratios were determined by the same procedures utilized for human apoA-I. Three turnover experiments. The study was conducted under an approved outpatient protocol at the General Clinical Research Center of The Methodist Hospital. Volunteers maintained their normal free-living diet throughout the experimental period and were instructed on the importance of avoiding high caloric intake. Supersaturated potassium iodide (1 g) was administered daily throughout the study period.
proapoA-I and mature apoA-I were radioiodinated with 12)I and 1311, respectively, by a modification of the McFarlane iodine monochloride method (15) . After radioiodination, apolipoproteins were passed over a Pharmacia PD-10 column (Sephadex G-25) equilibrated with injectable albumin solution in saline (Albuminar-5 from Armour) and further dialyzed against injectable sterile NaCl (0.15 M) to eliminate free iodine from the preparation. To determine the ability of the radioiodinated apolipoproteins to reassociate with native lipoproteins, tracer amounts of 125I-labeled preproapoA-I (1251-proapoA-I) and 1311-labeled mature apoA-I (131I-apoA-I) were incubated with plasma at 37°C for 10 min and the fractions density p < 1.063 g/ml (39,000 rpm for 18 hr at 4°C), p = 1.063-1.21 g/ml, and p > 1.21 g/ml (39,000 rpm for 40 hr at 4°C) were isolated by sequential ultracentrifugation in a Beckman 40.3 rotor.
Radioiodinated apolipoproteins were injected in association with HDL. 12 I-proapoA-I and 131I-apoA-I were incubated with 5 ml of normal human plasma for 10 min at 37°C. HDL were isolated by ultracentrifugation, extensively dialyzed against injectable saline (0.15 M), and diluted to the radioactive injectable dose with Albuminar-5. Before injection the material was twice passed through 0.22-,um Millipore filters and tested for sterility and pyrogenicity. Fasting subjects were injected with 20-30 uCi (1 Ci = 37 GBq) of radioiodinated apolipoproteins in 2-3 ml at 8:00 a.m. Blood samples were withdrawn at 10 min after the injection, at 3, 6, 9, and 24 hr thereafter, and then daily in the morning for each of the remaining 9 days. Urine also was collected between each blood sampling period. The blood samples were analyzed by sequential ultracentrifugation in a Beckman 40.3 rotor and the radioactivity was determined in the p < 1.063 g/ml supernate, in the HDL fraction, and in the p > 1.21 g/ml infranate. Total plasma-associated radioactivity also was determined. Lipoprotein quantitation was performed on each blood sample (16). apoA-I concentration in plasma and HDL was quantitated by radial immunodiffusion (17) .
For the determination of the 125I-proapoA-I and 1311-apoA-I specific activity, HDL apoproteins were subjected to isoelectrofocusing (9) . After staining, the portions of the gel corresponding to proapoA-I and mature apoA-I were cut out and their radioactivities were measured. The masses of proapoA-I and mature apoA-I in HDL were calculated from the HDL apoA-I concentration values and the proapoA-I and mature apoA-I mass ratio. Turnover Studies in Rats. Apolipoproteins were radioiodinated as described in the section on human studies. 125I1
proapoA-I and 1311-apoA-I were tested for lipoprotein reassociation capability with native lipoproteins by incubation with normal rat plasma or plasma containing added rat lymph chylomicrons (450 mg/dl as triglycerides). After incubation lipoproteins were isolated by ultracentrifugation as in the human protocol. Radioiodinated apolipoproteins, associated with chylomicrons or HDL, were injected into the rats. For this purpose, 125I-proapoA-I and 1311-apoA-I were incubated with 5 ml of lymph chylomicrons in 0.15 M NaCl (5300 mg/dl as triglycerides) or plasma for 10 min at 370C and the desired lipoprotein fractions were isolated by ultracentrifugation. Before injection, apoA-I-labelled chylomicrons and HDL were dialyzed extensively against injectable saline solution (0.15 M).
Throughout the study, male Sprague-Dawley rats weighing 200-250 g were utilized. Animals were prepared for the experiments by surgically inserting a PE50 cannula in the femoral vein under ether anesthesia (18) 15 ,Ci of radiolabeled lipoproteins in 0.3-0.5 ml was injected via the femoral cannula and the tubing was flushed with saline. Three minutes after the injection 0.3 ml of blood was obtained through the injection cannula, and the animals were sacrificed by aortic bleeding under ether anesthesia at 10 and 75 min and at 2, 4, 6, and 12 hr. Plasma was processed by ultracentrifugation in a Beckman 40.3 rotor for separation of the p < 1.063 g/ml supernatant, HDL, and p > 1.210 g/ml infranatant. Radioactivity was determined in plasma and in each isolated lipoprotein fraction. apoA-I concentrations in plasma and HDL were determined by radial immunodiffusion (17) . HDL cholesterol was determined by an enzymatic Boehringer Mannheim cholesterol assay kit. HDL apolipoproteins were separated by isoelectrofocusing and the stained bands corresponding to proapoA-I and mature apoA-I were cut out and their radioactivities were measured proapo-A-I and mature apoA-I specific activities were determined, as described for the human study, from the total apoA-I concentration in HDL and the proapoA-I to mature apoA-I mass ratio.
Calculation of the Turnover Parameters. Protein residence times and production (degradation) rates were determined by input-output analysis, assuming that the final portion of the curve was showing exponential decay (19, 20) . Specific activity curves were analyzed by a general stripping curve procedure and the area under the curve was calculated by integration (20) .
RESULTS
Human Studies. The in vitro reassociation studies indicated that human 125I-proapoA-I and 1311-apoA-I distributed among the lipoproteins virtually identically and most of the radioactivity was associated with HDL. When the distribu- tion of the radiotracers was determined in lipoprotein fractions isolated by ultracentrifugation, the percentage distribution among p < 1.063 g/ml supernatant, HDL, and p > 1.210 g/ml infranatant was, respectively, for 125I-proapoA-I 3.5%, 87.1%, and 9.4% and for "11-apoA-I 3.7%, 90.2%, and 6.5%.
A similar radioactivity distribution was found among the same lipoprotein fractions isolated by ultracentrifugaton from the plasma collected at each selected time point after injection. Table 1 shows the plasma lipid levels, HDL cholesterol, and apoA-I concentrations in plasma and in HDL for the two volunteers. The disappearance curves for 125I-proapoA-I and 131I-apoA-I in HDL are illustrated for both of the subjects in Fig. 1 . The specific activities were calculated with a proapoA-I to mature apoA-I mass ratio of 0.032 as determined with the pyridine/water dye elution method. proapo-A-I turnover time was extremely brief, with a calculated residence time of 0.13 day. At 24 hr, the specific activity was less than 3% of that determined at 10 min after the injection. The residence time of mature apoA-I in HDL was 3.9 days. In both of the subjects, the proapoA-I to mature apoA-I conversion was virtually completed between 9 and 24 hr after the injection. The 125I-proapoA-I specific activity curve intersected the 125I-apoA-I curve at its peak, consistent with the hypothesis that mature apoA-I is completely derived from proapoA-I in plasma. Table  2 . A proapoA-I to mature apoA-I mass ratio of 0.40 was utilized for the calculation of the specific activities. In the first set of experiments, 125I-proapoA-I and 131I-apoA-I associated with HDL were injected into fasted rats. Residence time for proapoA-I was 0.15 day and for mature apoA-I it was 0.28 day. The decline of the proapoA-I specific activity was rapid, but the curve did not intercept that of the newly formed mature apoA-I during the period of observation ( Fig.  2A) . Twelve hours after injection, conversion was 63% complete (Fig. 3) . In a second set of experiments, fasted animals were injected with 125I-proapoA-I and 131I-apoA-I associated with lymph chylomicrons. Three minutes after injection, plasma triglycerides reached 450 ± 53 mg/dl from initial values of 45 ± 5 g/ml; between 75 and 120 min triglyceridemia progressively declined to the baseline level. proapoA-I and mature apoA-I residence times were, respectively, 0.08 day and 0.26 day. The 125I-proapoA-I specific activity curve crossed the 125I-apoA-I specific activity curve at its peak, consistent with mature apoA-I being totally derived from proapoA-I (Fig. 2B) . Conversion had reached completion at 6 hr (Fig. 3) . These data suggested that proapoA-I conversion in plasma was accelerated by the presence of triglyceride-rich intestinal lipoproteins. A third set of experiments, utilizing animals fed oil-saturated ground chow and injected with HDL-associated 125I-proapoA-I and 131I-apoA-I, also supported this concept. Although plasma triglycerides were affected only modestly (98 ± 8 mg/dl vs 45 ± 4 mg/dl), conversion increased significantly as compared to the similarly injected fasted group of animals. Conversion was virtually completed in 12 hr (Fig. 3) . proapoA-I and mature apoA-I residence times were, respectively, 0.12 day and 0.25 day.
The 125I-proapoA-I specific activity curve intercepted the 125I-specific activity curve at the end of the 12-hr experiment (Fig. 2C) . proapoA-I and 1311-apoA-I (mature) in rats. 125I-proapoA-I and 1311-apoA-I were incubated with normal rat plasma or lymph chylomicrons (flotation constant Sf > 400 S) at 370C for 10 min and HDL or chylomicrons were reisolated by ultracentrifugation. (A) Fasted rats were injected with the HDL-radioiodinated apoA-I complex and the animals were sacrificed serially from 10 min after the injection. Plasma HDL were isolated by ultracentrifugation and proapoA-I and mature apoA-I were separated by isoelectrofocusing for quantitation of the associated radioactivity and the determination of the specific activity. Values were normalized to the 10-min point. (B) Fasted animals were injected with the chylomicron-radioiodinated apoA-I complex and the proapoA-I and mature apoA-I specific activities were determined. (C) Fed animals maintained on oil-saturated rat chow and injected with the HDL-radioiodinated apoA-I complex. proapoA-I and mature apoA-I specific activities were determined as for the other experiments. Each point is the average of three independent experiments. DISCUSSION apoA-I is the major protein component of HDL and is thought to occupy a surface position on the lipoprotein (21, 22) . apoA-I activates lecithin-cholesterol acyltransferase, which is the cholesterol-esterifying enzyme of plasma that is involved in the production of mature circulating HDL (23) . The liver and the intestine are presumably the only significant sites of synthesis of apoA-I in rat (1), mouse (24) , and baboon (25) , although recently Blue et al. (26) have reported that various peripheral tissues of the chicken have the ability to synthesize apoA-I. A common finding in these studies is that apoA-I is secreted as a proproteip. In plasma, human injected into fasted rats (v) or rats fed oil-saturated rat chow (A). A third group consisted of fasted rats injected with '25I-proapoA-I and 13'I-apoA-I associated with chylomicrons (0). After injection, plasma HDL were isolated by ultracentrifugation and proapoA-I and mature apoA-I were separated by isoelectrofocusing. Conversion progression was determined from the I251 radioactivity associated to proapoA-I and to mature apoA-I at each selected time point. Each point is the mean of three independent experiments + SD.
apoA-I is a polymorphic system consisting of proapoA-I as a minor component and a series of mature isoproteins that constitute more than 95% of the total mass of circulating apoA-I (6, 9) . In the rat, proapoA-I also is present in plasma with mature forms, but proapoA-I is more abundant in this species than in humans and accounts for more than 25% of the circulating apoA-I mass (10) . Because mature apoA-I does not appear in the mixture of secreted apoA-I isoforms in vitro, it has been hypothesized that mature apoA-I in vivo must be produced during circulation in plasma.
Three major questions remain unanswered concerning this proposed in vivo conversion. First, is proapoA-I quantitatively converted in vivo to the mature forms or does more than one catabolic pathway for proapoA-I exist? Available in vitro studies indicate that proapoA-I conversion to mature apoA-I never reaches completion, 30% at most, under the reported experimental conditions (12, 13) , leaving open the possibility that another proapoA-I catabolic pathway may exist. Second, is the conclusion from in vitro studies that the only apoA-I form secreted is proapoA-I also valid in vivo? Third, how are the conversion parameters modulated in plasma, with particular emphasis on the role of HDL and lymph chylomicrons, which are the major circulating pools of proapoA-I? In the present study we have addressed these important questions by characterizing quantitatively the plasma catabolism of proapoA-I and mature apoA-I in humans and in rats.
In the two human volunteers, the proapoA-I production rate matched closely the production rate of mature apoA-I (Table 1) . These data validate a necessary condition that the conversion to the mature form in vivo is the major proapoA-I catabolic pathway in plasma. Analysis of the radioactivity secreted in the urine at the early times after injection, when unconverted radioiodinAted proapoA-I is still circulating, also supports the conclusion that direct catabolism of proapoA-I is minimal in normal subjects. Further, the 125i-proapoA-I specific activity decay curve intercepts the 1251-mature apoA-I specific activity curve at its peak. Assuming a simple direct precursor-product relationship for conversion of proapoA-I to mature apoA-I in plasma, the results support the idea that in man the mature apoA-I pool in plasma is derived from proapoA-I. As a corollary, a direct mature apoA-I secretion is not necessary to maintain the plasma pool of mature apoA-I in a steady state. This conclusion agrees with the earlier data obtained in vitro utilizing cell and tissue cultures (6) (7) (8) , which demonstrated that mature apoA-I was not secreted.
Similar conclusions were reached from our experiments in rats. In all cases, proapoA-I production rate closely matched the mature apoA-I production rate ( Table 2) . Intersection of the proapoA-I and derived mature apoA-I specific activity curves occurred during the observation period in fasted animals that had been injected with radiolabeled apoA-I forms associated with chylomicrons but not in the animals injected with HDL-associated radiolabeled apoA-I forms. This observation is probably due to the slower rate of conversion when proapoA-I is associated with HDL. In fact, extrapolation of the nonintersecting in vivo specific activity curves in plasma (Fig. 2) and of the proapoA-I conversion progression curve (Fig. 3) predicts intersection between 12 and 18 hr after injection.
The possibility that the presence of specific lipoprotein classes in plasma modulates the rate of proapoA-I conversion is clearly indicated by the experiments conducted in rats. A higher rate of conversion, in fact, was observed when triglyceride-rich lipoproteins of intestinal origin were present in plasma or when radiolabeled proapoA-I was injected as a complex with lymph chylomicrons. proapoA-I is the major apoA-I constituent of rat mesenteric lymph chylomicrons and, in man, proapoA-I concentration increases dramatically on thoracic duct chylomicrons during active fat absorption (9) . Together these observations support the idea that a chylomicron-proapoA-I complex may be the preferred substrate for the proapoA-I propeptidase. Although the proportion of proapoA-I associated with plasma chylomicrons is small relative to the amount associated with HDL, the higher turnover rate of this pool easily could account for the majority of the proapoA-I processed.
The role that proapoA-I may have in the plasma catabolism of chylomicrons and the disposition of their lipid and protein components is not yet known. Conceivably, the high concentration of proapoA-I in the lymph chylomicrons may simply reflect the fact that these are newly secreted lipoproteins. In line with the data presented in this communication, nascent HDL also may contain predominantly proapoA-I since it is the only form of apoA-I secreted. Both newly secreted HDL from the liver and lymph chylomicrons from the intestine have relatively short lifetimes in plasma. Both nascent lipoproteins are processed immediately by enzymes (lipoprotein lipase acts on chylomicrons and lecithin: cholesterol acyltransferase on HDL) and there is exchange of lipids and apolipoproteins with other plasma lipoproteins, which profoundly affects their structure and composition. The ability of these newly secreted particles to undergo such rapid catabolic changes may depend on the presence of a transient protein component, such as proapoA-I, which stabilizes their structure at the time of secretion, directs their path of maturation in plasma, and is ultimately eliminated by a specific and rapid protease action. Perhaps full maturation of these newly secreted lipoproteins requires proapoA-I conversion.
In conclusion, our studies in vivo are consistent with the idea that conversion to mature apoA-I is the major catabolic pathway for proapoA-I in plasma. Moreover, direct secretion of mature apoA-I must be minimal, if it occurs at all, since proapoA-I conversion accounts for the majority (if not the totality) of the mature apoA-I produced in humans and rat in vivo. The data obtained in the rat suggest that a putative chylomicron-proapoA-I complex is the preferred substrate for the proapoA-I propeptidase, since the rate of conversion is increased during fat absorption or when chylomicrons are present in plasma. Further studies will be necessary to elucidate fully the functional significance of proapoA-I conversion in plasma, in particular as to whether the conversion terminates or initiates new functions for apoA-I.
